JP2020527331A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020527331A5 JP2020527331A5 JP2019567602A JP2019567602A JP2020527331A5 JP 2020527331 A5 JP2020527331 A5 JP 2020527331A5 JP 2019567602 A JP2019567602 A JP 2019567602A JP 2019567602 A JP2019567602 A JP 2019567602A JP 2020527331 A5 JP2020527331 A5 JP 2020527331A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- sequence
- polypeptide according
- nucleic acid
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 62
- 229920001184 polypeptide Polymers 0.000 claims description 57
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 57
- 108020004707 nucleic acids Proteins 0.000 claims description 20
- 102000039446 nucleic acids Human genes 0.000 claims description 20
- 150000007523 nucleic acids Chemical class 0.000 claims description 20
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 201000010099 disease Diseases 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 11
- 238000003776 cleavage reaction Methods 0.000 claims description 10
- 230000000415 inactivating effect Effects 0.000 claims description 10
- 230000007017 scission Effects 0.000 claims description 10
- 230000037361 pathway Effects 0.000 claims description 8
- 230000003248 secreting effect Effects 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 102000035195 Peptidases Human genes 0.000 claims description 5
- 108091005804 Peptidases Proteins 0.000 claims description 5
- 230000000295 complement effect Effects 0.000 claims description 5
- 238000001514 detection method Methods 0.000 claims description 5
- 102000016550 Complement Factor H Human genes 0.000 claims description 4
- 108010053085 Complement Factor H Proteins 0.000 claims description 4
- 108091035707 Consensus sequence Proteins 0.000 claims description 4
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 4
- 238000006243 chemical reaction Methods 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 4
- 208000002780 macular degeneration Diseases 0.000 claims description 4
- 102100025680 Complement decay-accelerating factor Human genes 0.000 claims description 2
- 101000856022 Homo sapiens Complement decay-accelerating factor Proteins 0.000 claims description 2
- 101000961414 Homo sapiens Membrane cofactor protein Proteins 0.000 claims description 2
- 102100039373 Membrane cofactor protein Human genes 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 102000023732 binding proteins Human genes 0.000 claims description 2
- 108091008324 binding proteins Proteins 0.000 claims description 2
- 108010047295 complement receptors Proteins 0.000 claims description 2
- 102000006834 complement receptors Human genes 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 102000034356 gene-regulatory proteins Human genes 0.000 claims description 2
- 108091006104 gene-regulatory proteins Proteins 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- 229940127557 pharmaceutical product Drugs 0.000 claims description 2
- 230000008482 dysregulation Effects 0.000 claims 2
- 102000004961 Furin Human genes 0.000 claims 1
- 108090001126 Furin Proteins 0.000 claims 1
- 101710118538 Protease Proteins 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 210000001775 bruch membrane Anatomy 0.000 description 2
- 108010078015 Complement C3b Proteins 0.000 description 1
- 102000003689 Complement Factor I Human genes 0.000 description 1
- 108090000044 Complement Factor I Proteins 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023140001A JP2023162355A (ja) | 2017-06-09 | 2023-08-30 | Ｃ３ｂ不活性化ポリペプチド |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1709222.2 | 2017-06-09 | ||
| GBGB1709222.2A GB201709222D0 (en) | 2017-06-09 | 2017-06-09 | C3b Inactivating Polypeptide |
| PCT/EP2018/065199 WO2018224663A1 (en) | 2017-06-09 | 2018-06-08 | C3b inactivating polypeptide |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023140001A Division JP2023162355A (ja) | 2017-06-09 | 2023-08-30 | Ｃ３ｂ不活性化ポリペプチド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020527331A JP2020527331A (ja) | 2020-09-10 |
| JP2020527331A5 true JP2020527331A5 (cg-RX-API-DMAC7.html) | 2021-07-26 |
| JP7341897B2 JP7341897B2 (ja) | 2023-09-11 |
Family
ID=59358410
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019567602A Active JP7341897B2 (ja) | 2017-06-09 | 2018-06-08 | Ｃ３ｂ不活性化ポリペプチド |
| JP2023140001A Pending JP2023162355A (ja) | 2017-06-09 | 2023-08-30 | Ｃ３ｂ不活性化ポリペプチド |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023140001A Pending JP2023162355A (ja) | 2017-06-09 | 2023-08-30 | Ｃ３ｂ不活性化ポリペプチド |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20200277360A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3634985A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7341897B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN111051337A (cg-RX-API-DMAC7.html) |
| GB (1) | GB201709222D0 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018224663A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201800620D0 (en) * | 2018-01-15 | 2018-02-28 | Univ Manchester | C3b Binding Polypeptide |
| GB201821082D0 (en) | 2018-12-21 | 2019-02-06 | Gyroscope Therapeutics Ltd | Combination of complement factors i and h, and vector encoding thereof |
| GB202006789D0 (en) | 2020-05-07 | 2020-06-24 | Univ Manchester | Detection of complement proteins |
| EP4165181A2 (en) | 2020-06-14 | 2023-04-19 | Vertex Pharmaceuticals Incorporated | Complement factor i-related compositions and methods |
| EP4214515A1 (en) | 2020-09-16 | 2023-07-26 | Complement Therapeutics Limited | Complementome assay |
| GB202107586D0 (en) | 2021-05-27 | 2021-07-14 | Complement Therapeutics Ltd | Inhibitory nucleic acids for Factor H family proteins |
| WO2023091875A1 (en) * | 2021-11-19 | 2023-05-25 | Ap Biosciences, Inc. | Bi-functional fusion proteins to complement pathways and method of inhibiting bone resorption |
| CN114317562B (zh) * | 2022-02-22 | 2023-06-13 | 辽宁省农业科学院 | 普通菜豆镰孢菌枯萎病抗病相关蛋白的编码基因PvEXO70及应用 |
| GB202203627D0 (en) | 2022-03-16 | 2022-04-27 | Univ Manchester | Agents for treating complement-related disorders |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999044625A1 (en) * | 1998-03-03 | 1999-09-10 | John Hopkins University | Smallpox inhibitor of complement enzymes (spice) protein and methods of inhibiting complement activation |
| GB9930659D0 (en) * | 1999-12-24 | 2000-02-16 | Bio Discovery Ltd | Inhibitors of complement activation |
| BRPI0712987A2 (pt) * | 2006-06-21 | 2012-04-10 | Musc Found For Res Dev | tratamento de doenças direcionado ao fator h do complemento |
| CA2803588A1 (en) * | 2010-06-22 | 2011-12-29 | The Regents Of The University Of Colorado, A Body Corporate | Antibodies to the c3d fragment of complement component 3 |
| WO2015023972A1 (en) * | 2013-08-16 | 2015-02-19 | Alexion Pharmaceuticals, Inc. | Treatment of graft rejection by administering a complement inhibitor to an organ prior to transplant |
| CN104231085B (zh) * | 2013-09-05 | 2017-03-15 | 复旦大学附属肿瘤医院 | 靶向特异性补体系统抑制剂、其制备方法及应用 |
| CN107427577A (zh) * | 2015-03-31 | 2017-12-01 | 韦斯夸尔德有限公司 | 具有蛋白酶可切割接头的肽构建体 |
-
2017
- 2017-06-09 GB GBGB1709222.2A patent/GB201709222D0/en not_active Ceased
-
2018
- 2018-06-08 EP EP18729681.9A patent/EP3634985A1/en active Pending
- 2018-06-08 US US16/620,383 patent/US20200277360A1/en not_active Abandoned
- 2018-06-08 JP JP2019567602A patent/JP7341897B2/ja active Active
- 2018-06-08 CN CN201880051653.9A patent/CN111051337A/zh active Pending
- 2018-06-08 WO PCT/EP2018/065199 patent/WO2018224663A1/en not_active Ceased
-
2023
- 2023-08-30 JP JP2023140001A patent/JP2023162355A/ja active Pending
-
2024
- 2024-02-09 US US18/438,008 patent/US20240336675A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020527331A5 (cg-RX-API-DMAC7.html) | ||
| JP7320090B2 (ja) | 第ｖｉｉｉ因子組成物、ならびに組成物の作製方法および用途 | |
| JP5813641B2 (ja) | 凝固第ｉｘ因子組成物ならびにそれを製造および使用する方法 | |
| JP6300885B2 (ja) | 第Ｘａ因子阻害剤に対する抗体およびその使用の方法 | |
| EP2970954B1 (en) | Modification of polypeptides | |
| CN102316893B (zh) | 因子Xa抑制剂的解毒剂及其与血液凝固剂组合使用的方法 | |
| RU2731507C1 (ru) | Gla домены в качестве нацеливающих агентов | |
| EP2022506B1 (en) | Method for the treatment of flavivirus infection, molecules and uses thereof | |
| JP2017527272A5 (cg-RX-API-DMAC7.html) | ||
| JP2013502459A5 (cg-RX-API-DMAC7.html) | ||
| RU2010151725A (ru) | Аминокислотные последовательности, направленные против cхcr4 и других gpcr, и соединения, включаюшие их | |
| UA75064C2 (en) | Modified porcine factor viii and its therapeutic use | |
| CN104379594B (zh) | 用于纯化重组因子Xa衍生物的方法 | |
| JP2024056926A (ja) | 第Ｘａ因子阻害剤に対する解毒剤 | |
| JP2006516113A5 (cg-RX-API-DMAC7.html) | ||
| CN116194466A (zh) | 编码重组转化生长因子(TGF)-β单体的溶瘤病毒及其用途 | |
| Teçza et al. | Enzyme kinetic and binding studies identify determinants of specificity for the immunomodulatory enzyme ScpA, a C5a inactivating bacterial protease | |
| JP2019030318A (ja) | 血液凝固第ｖｉｉ因子を含有する組成物におけるウイルス不活性化法 | |
| CN116507726A (zh) | 二肽基肽酶和亮氨酸氨基肽酶多肽变体 | |
| US20190100602A1 (en) | Anti-antithrombin single-domain antibodies and polypeptides comprising thereof | |
| Chenivesse et al. | Expression of a recombinant kringle V of human apolipoprotein (a): Antibody characterization and species specificity | |
| Carle | Development of cyclic peptide inhibitors of coagulation factor XIa for safer anticoagulation | |
| Storgaard | Design, Synthesis and Biological Activity of Novel Reversible Peptidyl FVIIa Inhibitors Rh-Catalyzed Enantioselective Synthesis of Diaryl Amines | |
| Litzenburger | A specific antidote for dabigatran: functional and structural characterization | |
| Roddick | Fusing the C-terminal tridecapeptide of hirudin to α1-proteinase inhibitor M358R accelerates its rate of thrombin inhibition |